Wall Street analyst estimates for Repligen Corporation (RGEN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
Analyst Consensus
| Strong Buy | 1 |
| Buy | 21 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 24 |
| Avg rating (1-5) | 0.96 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.46 | ||
| 2026-07-28 | $0.54 | $0.45 | +20.8% |
| 2026-05-05 | $0.48 | $0.38 | +26.3% |
| 2026-02-24 | $0.49 | $0.44 | +11.4% |
| 2025-10-28 | $0.46 | $0.42 | +9.5% |
| 2025-07-29 | $0.37 | $0.40 | -7.5% |
| 2025-04-29 | $0.39 | $0.35 | +11.4% |
| 2025-02-20 | $0.44 | $0.41 | +7.3% |
Valuation Ratios
| P/E Ratio | 256.08 |
| Price / Book | 5.06 |
| EV / EBITDA | 88.47 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104.5M | $141.2M | $194.0M | $270.2M | $366.3M | $670.5M | $801.5M | $632.4M | $634.4M | $738.3M |
| Cost of Revenue | $47.1M | $67.0M | $86.0M | $132.0M | $171.9M | $279.3M | $345.8M | $353.9M | $359.8M | $390.6M |
| Gross Profit | $57.4M | $74.2M | $108.1M | $138.2M | $194.4M | $391.3M | $455.7M | $278.4M | $274.6M | $347.6M |
| Research & Development | $7.4M | $8.7M | $15.8M | $19.4M | $19.7M | $34.3M | $43.9M | $42.7M | $43.2M | $54.2M |
| Selling, General & Admin | $30.9M | $51.5M | $66.3M | $78.7M | $93.4M | $183.9M | $215.8M | $218.6M | $263.4M | $290.5M |
| Operating Expenses | $38.2M | $60.2M | $82.1M | $98.1M | $113.1M | $224.0M | $231.0M | $230.7M | $309.8M | $288.0M |
| Operating Income | $16.0M | $14.0M | $26.0M | $40.1M | $81.3M | $167.2M | $224.7M | $47.7M | -$35.1M | $59.6M |
| EBITDA | $24.6M | $24.1M | $41.8M | $56.3M | $98.4M | $203.3M | $277.3M | $145.3M | $80.3M | $164.3M |
| Interest Expense | $3.8M | $6.4M | $6.7M | $9.3M | $12.1M | $12.7M | $3.0M | $10.0M | $22.6M | $23.2M |
| Pre-tax Income | $11.7M | $7.2M | $21.4M | $26.2M | $59.2M | $153.5M | $219.1M | $56.7M | -$27.0M | $62.4M |
| Income Tax | $11,000 | -$21.1M | $4.8M | $4.7M | -$709,000 | $25.3M | $33.2M | $21.1M | -$1.5M | $13.5M |
| Net Income | $11.7M | $28.4M | $16.6M | $21.4M | $59.9M | $128.3M | $186.0M | $35.6M | -$25.5M | $48.9M |
| EPS | $0.35 | $0.74 | $0.38 | $0.44 | $1.14 | $2.33 | $3.35 | $0.64 | $-0.46 | $0.87 |
| EPS (Diluted) | $0.34 | $0.72 | $0.37 | $0.44 | $1.11 | $2.24 | $3.24 | $0.63 | $-0.46 | $0.86 |
| Shares Outstanding (Diluted) | $34.1M | $39.1M | $45.5M | $49.2M | $53.9M | $57.3M | $57.5M | $56.4M | $55.9M | $56.6M |
Price
| Price | $189.50 |
| Market Cap | $10.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATR · AVTR · BAX · BIO · CRL · DVA · GMED
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of RGEN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks